NIH Funding Opportunities

Transgender People: Immunity, Prevention, and Treatment (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-20-054 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)

Funding Opportunity PAR-20-053 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.

Impact of Alcohol on the Onset and Progression of Alzheimers Disease and Its Related Dementias (R01 - Clinical Trial Optional)

Funding Opportunity RFA-AA-20-006 from the NIH Guide for Grants and Contracts. The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimers disease and its related dementias. Recent longitudinal studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimers disease and vascular dementia. Even moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy and frequent alcohol drinking to dementias in aging populations, mechanisms contributing to this relationship are not well understood. With this FOA, we solicitate research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimers disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research.

Limited Competition: Biospecimen Bank to Support NCI Early-Phase and Experimental Clinical Trials (U24 Clinical Trials Not Allowed)

Funding Opportunity RFA-CA-20-003 from the NIH Guide for Grants and Contracts. The main goal of this limited competition Funding Opportunity Announcement (FOA) is to continue the state-of the-art biobanking infrastructure and operations for early-stage and experimental clinical trials sponsored by the National Cancer Institute (NCI). The biobanking needs of the following NCI clinical trial programs will be supported: Experimental Therapeutics Clinical Trials Network (ETCTN), and Other NCI-supported early and experimental trials. Currently, this biobanking infrastructure supporting NCI early experimental clinical trials is part of a biobank serving primarily another NCI program, National Clinical Trials Network (NCTN). Through a separate U24 award under this FOA, the NCI aims to separate the existing ETCTN-serving biobanking infrastructure and operation from the current NCTN Biobank. This separated entity will be termed: Early-Phase and Experimental Clinical Trials Biospecimen Bank (also referred to as EET Biobank). Although the EET Biobank and the "parent" NCTN Biobank may be hosted in the same institution, they are expected to become independent operations with separate leaderships. EET Biobank will be responsible for collecting, processing, storing a variety of human specimens from patients with cancer who are participating in NCI-funded ETCTN and other NCI-supported early and experimental clinical trials. The responsibilities of EET Bank will also include maintenance of up-to-date specimen inventory and specimen distribution to qualified NCI-approved trial investigators and research laboratories.

NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed)

Funding Opportunity PAR-20-051 from the NIH Guide for Grants and Contracts. The NEI Center Core Grant combines three or more Resource and/or Service Cores for a group of R01 investigators to enhance their research, consolidate resources, avoid duplication of efforts, and/or contribute to cost effectiveness by providing a service with lower costs or higher quality than could be attempted for independent projects by several individual Program Directors/Principal Investigators (PD(s)/PI(s)).

Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)

Funding Opportunity RFA-DK-19-033 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for Exploratory Centers for Interdisciplinary Research in Benign Urology (P20). A major goal of this program is to build interdisciplinary research teams. The program seeks innovative, high-riskhigh-reward Research Projects that utilize integrative approaches to address questions relevant to benign genitourinary diseases or disorders bringing together investigators with complementary expertise. Studies involving human subjects or tissues and small, innovative, pilot and feasibility clinical studies are encouraged. The following expertise must be included in the proposed Research Project: 1) researchers new to the investigation of benign genitourinary diseases or disorders and 2) clinical urology expertise. Additional expertise may also be included, as needed. In addition to the scientific Research Project, each Exploratory Center must include an Administrative Core with an Educational Enrichment Program. As part of the NIDDK's efforts to expand and enhance benign urology research and the base of urologic researchers, the Exploratory Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.

Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)

Funding Opportunity RFA-RM-19-012 from the NIH Guide for Grants and Contracts. Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund data sets, including generating hypotheses and catalyzing discoveries. Award recipients are also asked to provide feedback on the utility of the Common Fund data resources.

Limited Competition for the Closeout of the SEARCH for Diabetes in Youth Cohort Study (R01 Clinical Trial Not Allowed)

Funding Opportunity RFA-DK-19-507 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to complete the SEARCH for Diabetes in Youth Cohort Study. SEARCH has recruited a cohort of youth with diabetes who have been followed longitudinally. The purpose of this FOA is to complete data analyses and disseminate scientific findings regarding the evolution of diabetes-related complications, including mortality, and processes of care and quality of life.

NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)

Funding Opportunity PAR-20-052 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Leadership Award for Alzheimer's Disease and Related Dementias Research (R35 Clinical Trial Not Allowed)

Funding Opportunity RFA-AG-21-007 from the NIH Guide for Grants and Contracts. NIA invites applications for the Leadership Award for Alzheimer's Disease and Related Dementias Research (R35). Applicants will be supported to develop and implement innovative multidisciplinary research and mentoring programs through an interchange of ideas that enable individuals and their institutions to strengthen existing programs and the development of new research programs that are specific to the goals/milestones of the NIH Alzheimer's Disease and Alzheimer's Disease Related Dementias Summits.

Dysregulation and Proximal Risk for Suicide (R01 Clinical Trial Optional)

Funding Opportunity RFA-MH-20-327 from the NIH Guide for Grants and Contracts. A major goal of research on suicide is to improve our understanding of who is at most risk, why people transition from suicidal thoughts to action, and when to intervene ( Prioritized Research Agenda for Suicide Prevention, Short-term Objective 1.C). Risk is a dynamic process and suicide attempts are often preceded by acute stressors. While many studies of suicide risk focus on emotion dysregulation, fewer studies have examined arousal and regulation and how these domains dynamically shape emotional and cognitive functions such as response to reward, frustrative non-reward, cognitive flexibility and control, or decision-making. Very few studies in the NIMH portfolio on suicide risk have focused on proximal risk. This Funding Opportunity Announcement (FOA) will fund research that will address these gaps by providing an understanding of the mechanisms of how dysregulation interacts with cognition and negative and positive valence in order to determine time-varying risk, and then to identify modifiable targets for timely interventions during highrisk periods. A companion RFA, RFA-MH-19-326 , uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data may wish to apply to this FOA using the R01 mechanism.

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional)

Funding Opportunity RFA-MH-20-326 from the NIH Guide for Grants and Contracts. A major goal of research on suicide is to improve our understanding of who is at most risk why people transition from suicidal thoughts to action, and when to intervene (Prioritized Research Agenda for Suicide Prevention, Short-term Objective 1.C). Risk is a dynamic process and suicide attempts are often preceded by acute stressors. While many studies of suicide risk focus on emotion dysregulation, fewer studies have examined arousal and regulation and how these domains dynamically shape emotional and cognitive functions such as response to reward, frustrative non-reward, cognitive flexibility and control, or decision-making. Very few studies in the NIMH portfolio on suicide risk have focused on proximal risk. This Funding Opportunity Announcement (FOA) will fund research that will address these gaps by providing an understanding of the mechanisms of how dysregulation interacts with Cognition and Negative and Positive Valence in order to determine time-varying risk, and then to identify modifiable targets for timely interventions during highrisk periods. This FOA uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data may wish to apply using the R01 mechanism, RFA-MH-19-327

Páginas